Medistim — Earnings Release 2017

Aug 15, 2017

Results for the first half of 2017 for Medistim ASA

Results for the first half of 2017 for Medistim ASA

Sales ended at MNOK 69.2 for the quarter (MNOK 67.2). Sales for the

1st half increased by 8.2 % and ended at MOK 143.5 (MNOK 132.7).

Currency neutral growth of own products was 4.7 % and was negatively

impacted by delayed flow probe deliveries amounting to MNOK 5.5.

Currency neutral growth of own products was 10.7 % for the 1st half.

Operating profit (EBIT) for the quarter ended at MNOK 13.6 (MNOK

17.1). Operating profit for the 1st half ended at MNOK 29.7 (MNOK

30.6).

Medistim continues to growth in the US. Currency neutral growth for

the quarter was 11.1 %.

MiraQ, Medistims newest system platform, was cleared for sale in

China in August.

Medistim paid a dividend based upon 2016 results the 8th of May with

MNOK 31.5, NOK 1.75 per share (NOK 1.65 per share).